IVIM Technology, Inc.
KKRX:4604702,595.00
KRW
-65.00
(-2.44%)
ISIN
KR7460470008
Return %
Stock
S&P 500
1Y
-20.40
14.20
3Y
- -
81.12
5Y
- -
68.34
Capital Structure
KRW
•
in mil. unless spec.Working Capital
KRW
•
in mil. unless spec.Growth Rates
KRW
•
in mil. unless spec.Quarterly Revenue
KRW
•
in mil. unless spec.Quarterly Earnings Per Share
KRW
•
in mil. unless spec.Quarterly Dividends Per Share
KRW
•
in mil. unless spec.Company Description
- CEO
- Pil-Han Kim
- Full Time Employees
- 37
- Sector
- Health technology
- Industry
- Medical specialties
- Address
- #B-415, Daedeok BizCenter 17 Daejeon DE South Korea 34013
- IPO Date
- Aug 6, 2024
- Website
- ivimtech.com
- Similar Companies
- Business
- IVIM Technology, Inc. (460470.KQ) develops and markets intravital microscopy (IVM) platforms for in vivo live-cell imaging in preclinical research. The company offers an integrated product line including IVM-C3, a confocal system for multi-color 3D/4D imaging of living cells and tissues with enhanced detection efficiency, optical resolution, and contrast; IVM-M3, a two-photon system for deep-tissue imaging using tunable near-infrared wavelengths and second-harmonic generation; IVM-CM3, a dual-mode confocal and two-photon system with tunable laser from 690nm to 1050nm for high-contrast imaging near skin or deep in tumors; IVM-MS3, a compact all-in-one two-photon smart system optimized at 920nm for cost-effective deep-tissue applications; IVM-CMS3, the world's smallest dual-mode confocal/two-photon system with one-click mode switching for functional intravital imaging; and IVM-FS, a free-space customizable system for larger animals such as ferrets and rabbits. IVIM Technology also provides preclinical contract research organization (CRO) services featuring intravital imaging analysis of drug efficacy, delivery, and dynamic molecular/cellular mechanisms in organs including liver, lung, brain, kidney, skin, and lymph nodes; in vivo imaging training, seminars, workshops, and accessories such as imaging chambers, holders, labeled antibodies, and AI-powered image denoisers. Founded in 2017 and headquartered in Daejeon, South Korea, the company operates a global R&D center and animal facilities, serving academic institutions and pharmaceutical firms across North America, Europe, and Asia including Harvard University, Johns Hopkins, Sanofi, Seoul National University Hospital, and Peking University. In recent developments, IVIM Technology expanded its CRO services, earning recognition as one of the APAC Top 10 Bioanalytical Service Providers by Life Sciences Magazine in December 2023; reported quarterly revenue of $721.64 million in Q2 2025, up 380.57% year-over-year; and continues active global outreach through 2025 webinars, workshops, and exhibitions such as JNS 2025 and SCSOK 2025.